Vanda Pharmaceuticals reported a quarterly loss of $0.82 per share, wider than the Zacks Consensus Estimate loss of $0.53 and worse than the $0.50 loss a year ago. The miss versus expectations and year-over-year deterioration point to weaker operating performance. The update is likely to pressure VNDA shares, though the impact is stock-specific rather than sector-wide.
Vanda Pharmaceuticals reported a quarterly loss of $0.82 per share, wider than the Zacks Consensus Estimate loss of $0.53 and worse than the $0.50 loss a year ago. The miss versus expectations and year-over-year deterioration point to weaker operating performance. The update is likely to pressure VNDA shares, though the impact is stock-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.62
Ticker Sentiment
